|
1
|
Ferlay JSI, Ervik M, Dikshit R, Eser S,
Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012
v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.
11 (Internet). International Agency for Research on Cancer (Lyon,
France). 2013.http://globocan.iarc.frAccessed. January
23–2015
|
|
2
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scagliotti GV, De Marinis F, Rinaldi M,
Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla
G, et al: Phase III randomized trial comparing three platinum-based
doublets in advanced non-small-cell lung cancer. J Clin Oncol.
20:4285–4291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, et al: Randomized, multinational, phase III study of
docetaxel plus platinum combinations versus vinorelbine plus
cisplatin for advanced non-small-cell lung cancer: The TAX 326
study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S and Shimizu N:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gerber DE, Gandhi L and Costa DB:
Management and future directions in non-small cell lung cancer with
known activating mutations. Am Soc Clin Oncol Educ Book. e353–e365.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee JY, Lim SH, Kim M, Kim S, Jung HA,
Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, et al: Is there any
predictor for clinical outcome in EGFR mutant NSCLC patients
treated with EGFR TKIs? Cancer Chemother Pharmacol. 73:1063–1070.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang SF, Liu HP, Li LH, Ku YC, Fu YN,
Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al: High frequency
of epidermal growth factor receptor mutations with complex patterns
in non-small cell lung cancers related to gefitinib responsiveness
in Taiwan. Clin Cancer Res. 10:8195–8203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin
SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, et al: Complex
mutation patterns of epidermal growth factor receptor gene
associated with variable responses to gefitinib treatment in
patients with non-small cell lung cancer. Lung Cancer. 53:311–322.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang SW, Ho CF, Chan KW, Cheng MC, Shien
JH, Liu HJ and Wang CY: The genotyping of infectious bronchitis
virus in Taiwan by a multiplex amplification refractory mutation
system reverse transcription polymerase chain reaction. J Vet Diagn
Invest. 26:721–733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT and Christian MC: New guidelines to evaluate the
response to treatment in solid tumors. European organization for
research and treatment of cancer, national cancer institute of the
united states, national cancer institute of Canada. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR,
Zhu JQ, Wang K, Yang XN, Chen G, Yang JJ, et al: Epidermal growth
factor receptor double activating mutations involving both exons 19
and 21 exist in Chinese non-small cell lung cancer patients. Clin
Oncol (R Col Radiol). 19:499–506. 2007. View Article : Google Scholar
|
|
18
|
Masago K, Fujita S, Kim YH, Ichikawa M,
Hatachi Y, Fukuhara A, Nagai H, Irisa K, Mio T and Mishima M:
Epidermal growth factor receptor (EGFR) double-activating somatic
mutations in exons 19 and 21 in Japanese non-small cell lung cancer
patients. Cancer Genet Cytogenet. 195:179–182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Masago K, Togashi Y, Fukudo M, Terada T,
Irisa K, Sakamori Y, Fujita S, Kim YH, Mio T and Inui K: Good
clinical response to erlotinib in a non-small cell lung cancer
patient harboring multiple brain metastases and a double active
somatic epidermal growth factor gene mutation. Case Rep Oncol.
3:98–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keam B, Kim DW, Park JH, Lee JO, Kim TM,
Lee SH, Chung DH and Heo DS: Rare and complex mutations of
epidermal growth factor receptor and efficacy of tyrosine kinase
inhibitor in patients with non-small cell lung cancer. Int J Clin
Oncol. 19:594–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng L, Song ZG and Jiao SC: Efficacy
analysis of tyrosine kinase inhibitors on rare non-small cell lung
cancer patients harboring complex EGFR mutations. Sci Rep.
4:61042014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hata A, Yoshioka H, Fujita S, Kunimasa K,
Kaji R, Imai Y, Tomii K, Iwasaku M, Nishiyama A and Ishida T:
Complex mutations in the epidermal growth factor receptor gene in
non-small cell lung cancer. J Thorac Oncol. 5:1524–1528. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K and Archer V: Gefitinib plus best supportive care in
previously treated patients with refractory advanced non-small-cell
lung cancer: Results from a randomised, placebo-controlled,
multicentre study (iressa survival evaluation in lung cancer).
Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bai H, Wang Z, Chen K, Zhao J, Lee JJ,
Wang S, Zhou Q, Zhuo M, Mao L, An T, et al: Influence of
chemotherapy on EGFR mutation status among patients with
non-small-cell lung cancer. J Clin Oncol. 30:3077–3083. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gerlinger M, Rowan AJ, Horswell S, Larkin
J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A,
Tarpey P, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gerlinger M, Horswell S, Larkin J, Rowan
AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos
CR, et al: Genomic architecture and evolution of clear cell renal
cell carcinomas defined by multiregion sequencing. Nat Genet.
46:225–233. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang J, Fujimoto J, Zhang J, Wedge DC,
Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al: Intratumor
heterogeneity in localized lung adenocarcinomas delineated by
multiregion sequencing. Science. 346:256–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Bruin EC, McGranahan N, Mitter R, Salm
M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan
AJ, et al: Spatial and temporal diversity in genomic instability
processes defines lung cancer evolution. Science. 346:251–256.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee SY, Kim MJ, Jin G, Yoo SS, Park JY,
Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, et al: Somatic mutations
in epidermal growth factor receptor signaling pathway genes in
non-small cell lung cancers. J Thorac Oncol. 5:1734–1740. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Benedettini E, Sholl LM, Peyton M, Reilly
J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al:
Met activation in non-small cell lung cancer is associated with de
novo resistance to EGFR inhibitors and the development of brain
metastasis. Am J Pathol. 177:415–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yano S, Yamada T, Takeuchi S, Tachibana K,
Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, et
al: Hepatocyte growth factor expression in EGFR mutant lung cancer
with intrinsic and acquired resistance to tyrosine kinase
inhibitors in a Japanese cohort. J Thorac Oncol. 6:2011–2017. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ludovini V, Bianconi F, Pistola L, Chiari
R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A,
Flacco A, et al: Phosphoinositide-3-kinase catalytic alpha and KRAS
mutations are important predictors of resistance to therapy with
epidermal growth factor receptor tyrosine kinase inhibitors in
patients with advanced non-small cell lung cancer. J Thorac Oncol.
6:707–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shih JY, Gow CH and Yang PC: EGFR mutation
conferring primary resistance to gefitinib in non-small-cell lung
cancer. N Engl J Med. 353:207–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rolfo C, Castiglia M, Hong D, Alessandro
R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F,
Carreca AP, et al: Liquid biopsies in lung cancer: The new ambrosia
of researchers. Biochim Biophys Acta. 1846:539–546. 2014.PubMed/NCBI
|
